Impala Nordic

Bifogade filer

OncoZenge Q1 2026 & CTA

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

OncoZenge - Report Comment: Green light to initiate Phase III

2026-05-26 15:51:00

Impala Nordic comments on OncoZenge AB (publ) ("OncoZenge" or the "Company") Q1 2026 and the receipt of full European regulatory approval to initiate the pivotal Phase III trial of BupiZenge™.

The CTA approval is one of the most important milestones in the Company's history, removes the primary near-term uncertainty, and triggers committed financing from both Yangtian Pharma and Molteni Farmaceutici amounting to approximately 21 MSEK. The spotlight now shifts decisively to first patient enrollment, recruitment pace, and ultimately trial readout.

Click here to read the comment.

About Impala Nordic

Impala Nordic provides equity research, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Impala Nordic

Bifogade filer

Prenumeration

Vem äger bolaget?

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden